NG-52 | CAS#212779-48-1 | CDK inhibitor

MedKoo Cat#: 530460 | Name: NG-52

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NG-52 is a tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p (IC50s = 7 and 2 µM, respectively).

Chemical Structure

NG-52

CAS#212779-48-1

Theoretical Analysis

MedKoo Cat#: 530460

Name: NG-52

CAS#: 212779-48-1

Chemical Formula: C16H19ClN6O

Exact Mass: 346.1309

Molecular Weight: 346.82

Elemental Analysis: C, 55.41; H, 5.52; Cl, 10.22; N, 24.23; O, 4.61

Price and Availability

Size	Price	Availability
100mg	USD 850.00	2 Weeks
200mg	USD 1,650.00	2 Weeks
500mg	USD 2,250.00	2 Weeks
1g	USD 3,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

NG-52; NG 52; NG52. Compound 52

IUPAC/Chemical Name

2-((6-((3-chlorophenyl)amino)-9-isopropyl-9H-purin-2-yl)amino)ethan-1-ol

InChi Key

XZEFMZCNXDQXOZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H19ClN6O/c1-10(2)23-9-19-13-14(20-12-5-3-4-11(17)8-12)21-16(18-6-7-24)22-15(13)23/h3-5,8-10,24H,6-7H2,1-2H3,(H2,18,20,21,22)

SMILES Code

CC(C)N1C2=NC(NCCO)=NC(NC3=CC=CC(Cl)=C3)=C2N=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM.

In vitro activity:

This study showed that NG52 dose-dependently inhibited the proliferation of glioma U87 and U251 cell lines with IC50 values of 7.8 ± 1.1 and 5.2 ± 0.2 μM, respectively, meanwhile it potently inhibited the proliferation of primary glioma cells. This study further revealed that NG52 (12.5-50 μM) effectively inhibited the phosphorylation of PDHK1 at Thr338 site and the phosphorylation of PDH at Ser293 site in U87 and U251 cells, resulting in more pyruvic acid entering the Krebs cycle with increased production of ATP and ROS. Reference: Acta Pharmacol Sin. 2021 Apr;42(4):633-640. https://pubmed.ncbi.nlm.nih.gov/32737469/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMF	15.0	43.25
	DMSO	53.0	152.82
	DMSO:PBS (pH 7.2)	0.1	0.29
	Ethanol	14.0	40.37

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 346.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Lu Y, Zhao N, Wu Y, Yang S, Wu Q, Dong Q, Du Y. Inhibition of PGK1 attenuates autoimmune myocarditis by reprogramming CD4+ T cells metabolism. Cardiovasc Res. 2023 Feb 2:cvad029. doi: 10.1093/cvr/cvad029. Epub ahead of print. PMID: 36726197. 2. Wang WL, Jiang ZR, Hu C, Chen C, Hu ZQ, Wang AL, Wang L, Liu J, Wang WC, Liu QS. Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacol Sin. 2021 Apr;42(4):633-640. doi: 10.1038/s41401-020-0465-8. Epub 2020 Jul 31. PMID: 32737469; PMCID: PMC8115168.

In vitro protocol:

In vivo protocol:

TBD

Oska N, Awad AM, Eltanani S, Shawky M, Naghdi A, Yumnamcha T, Singh LP, Ibrahim AS. Glyceraldehyde-3-Phosphate Dehydrogenase/1,3-Bisphosphoglycerate-NADH as Key Determinants in Controlling Human Retinal Endothelial Cellular Functions: Insights from Glycolytic Screening. J Biol Chem. 2025 Mar 28:108472. doi: 10.1016/j.jbc.2025.108472. Epub ahead of print. PMID: 40158853.